Physician profile
Ryan T Trauring
NPI 1700900016
$677.18
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.70 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $139.47 | 2019 | |
| Lilly USA, LLC | $57.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.60 | 2019 | |
| Merck Sharp & Dohme LLC | $44.99 | 2019 | |
| Astellas Pharma US INC | $26.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.77 | 2019 | |
| Amarin Pharma, INC. | $16.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.88 | 2019 | |
| Amgen INC. | $14.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.37 | 2019 | |
| Allergan, INC. | $12.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.24 | 2019 | |
| Pfizer INC. | $11.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Trauring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.